2-Methoxyestradiol inhibits hypoxia-inducible factor 1α, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma

Clinical Cancer Research

Volumn 10, Issue 24, 2004, Pages 8665-8673

  Ricker, Justin L ^a   Chen, Zhong ^a   Yang, Xin Ping ^a   Pribluda, Victor S ^b   Swartz, Glenn M ^b   Van Waes, Carter ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b ENTREMED INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 7; CYTOKINE; DNA; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PACLITAXEL; PROTEIN BCL 2; SMALL INTERFERING RNA; VASCULOTROPIN;

ADVANCED CANCER; ANGIOGENESIS; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DNA BINDING; DRUG EFFICACY; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HEAD AND NECK CARCINOMA; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; CARCINOMA, SQUAMOUS CELL; CARRIER PROTEINS; CASPASE 3; CASPASE 7; CASPASES; CELL DIVISION; CELL HYPOXIA; DRUG THERAPY, COMBINATION; ENZYME ACTIVATION; ESTRADIOL; FEMALE; G2 PHASE; HEAD AND NECK NEOPLASMS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MICE, INBRED BALB C; MICE, SCID; MICROCIRCULATION; PACLITAXEL; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 11144239579     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1393     Document Type: Article

References (46)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999;49:8-31.
2. Beasley NJ, Wykoff CC, Watson PH, et al. Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. Cancer Res 2001;61:5262-7.
3. Semenza GL. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 2002;8(Suppl 4):S62-7.
4. Aebersold DM, Burri P, Beer KT, et al. Expression of hypoxia-inducible factor-1α: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 2001;61:2911-6.
5. Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002;53:1192-202.
6. Zagzag D, Zhong H, Scalzitti JM, Laughner E, Simons JW, Semenza GL. Expression of hypoxia-inducible factor 1α in brain tumors: association with angiogenesis, invasion, and progression. Cancer 2000;88:2606-18.
7. Bos R, van der Groep P, Greijer AE, et al. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 2003;97:1573-81.
8. Bachtiary B, Schindl M, Potter R, et al. Overexpression of hypoxia-inducible factor 1alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clin Cancer Res 2003;9:2234-40.
9. Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996;16:4604-13.
10. Erler JT, Cawthorne CJ, Williams KJ, et al. Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. Mol Cell Biol 2004;24:2875-89.
11. Chen Z, Malhotra PS, Thomas GR, et al. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res 1999;5:1369-79.
12. Harkins C, Chen Z, Yeh NT, Rudy S, Van Waes C. Serum cytokine levels after therapy as a predictor of prognosis and treatment response in head and neck squamous cell carcinoma [abstract]. Proceedings of the 94th Annual AACR Meeting; 2003 Jul 11-14; Washington, DC. Philadelphia, PA: American Association for Cancer Research; 2003.
13. Mabjeesh NJ, Escuin D, LaVallee TM, et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003;3:363-75.
14. Fotsis T, Zhang Y, Pepper MS, et al. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 1994;368:237-9.
15. Klauber N, Parangi S, Flynn E, Hamel E, D'Amato RJ. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and Taxol. Cancer Res 1997;57:81-6.
16. Huober JB, Nakamura S, Meyn R, Roth JA, Mukhopadhyay T. Oral administration of an estrogen metabolite-induced potentiation of radiation antitumor effects in presence of wild-type p53 in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2000;48:1127-37.
17. Schumacher G, Neuhaus P. The physiological estrogen metabolite 2-methoxyestradiol reduces tumor growth and induces apoptosis in human solid tumors. J Cancer Res Clin Oncol 2001;127:405-10.
18. Chauhan D, Catley L, Hideshima T, et al. 2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells. Blood 2002;100:2187-94.
19. Dingli D, Timm M, Russell SJ, Witzig TE, Rajkumar SV. Promising preclinical activity of 2-methoxyestradiol in multiple myeloma. Clin Cancer Res 2002;8:3948-54.
20. Shin DM, Lippman SM. Paclitaxel-based chemotherapy for recurrent and/or metastatic head and neck squamous cell carcinoma: current and future directions. Semin Oncol 1999;26:100-5.
21. Kumar N. Taxol-induced polymerization of purified tubulin: mechanism of action. J Biol Chem 1981;256:10435-41.
22. Krause CJ, Carey TE, Ott RW, Hurbis C, McClatchey KD, Regezi JA. Human squamous cell carcinoma: establishment and characterization of new permanent cell lines. Arch Otolaryngol 1981;107:703-10.
23. Longley DB, Allen WL, McDermott U, et al. The roles of thymidylate synthase and p53 in regulating fas-mediated apoptosis in response to antimetabolites. Clin Cancer Res 2004;10:3562-71.
24. LaVallee TM, Zhan XH, Johnson MS, et al. 2-Methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway. Cancer Res 2003;63:468-75.
25. Chauhan D, Li G, Sattler M, et al. Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cells. Oncogene 2003;22:6296-300.
26. Lambert C, Apel K, Biesalski HK, Frank J. 2-Methoxyestradiol induces caspase-independent, mitochondria-centered apoptosis in DS-sarcoma cells. Int J Cancer 2004;108:493-501.
27. Karbowski M, Spodnik JH, Teranishi M, et al. Opposite effects of microtubule-stabilizing and microtubule-destabilizing drugs on biogenesis of mitochondria in mammalian cells. J Cell Sci 2001;114:281-91.
28. Amant F, Lottering ML, Joubert A, Thaver V, Vergote I, Lindeque BG. 2-Methoxyestradiol strongly inhibits human uterine sarcomatous cell growth. Gynecol Oncol 2003;91:299-308.
29. Lin HL, Liu TY, Chau GY, Lui WY, Chi CW. Comparison of 2-methoxyestradiol-induced, docetaxel-induced, and paclitaxel-induced apoptosis in hepatoma cells and its correlation with reactive oxygen species. Cancer 2000;89:983-94.
30. Amorino GP, Freeman ML, Choy H. Enhancement of radiation effects in vitro by the estrogen metabolite 2-methoxyestradiol. Radiat Res 2000;153:384-91.
31. Moeller BJ, Cao Y, Li CY, Dewhirst MW. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 2004;5:429-41.
32. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995;270:1230-7.
33. Gerber HP, Condorelli F, Park J, Ferrara N. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes: Fit-1, but not Flk-1/KDR, is up-regulated by hypoxia. J Biol Chem 1997;272:23659-67.
34. Krishnamachary B, Berg-Dixon S, Kelly B, et al. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res 2003;63:1138-43.
35. Salceda S, Caro J. Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions: its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 1997;272:22642-7.
36. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271-5.
37. Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999;59:5830-5.
38. Yang ZZ, Zhang AY, Yi FX, Li PL, Zou AP. Redox regulation of HIF-1alpha levels and HO-1 expression in renal medullary interstitial cells. Am J Physiol Renal Physiol 2003;284:F1207-15.
39. Krajewska M, Zapata JM, Meinhold-Heerlein I, et al. Expression of Bcl-2 family member Bid in normal and malignant tissues. Neoplasia 2002;4:129-40.
40. Fukazawa T, Walter B, Owen-Schaub LB. Adenoviral Bid overexpression induces caspase-dependent cleavage of truncated Bid and p53-independent apoptosis in human non-small cell lung cancers. J Biol Chem 2003;278:25428-34.
41. Zinkel SS, Ong CC, Ferguson DO, et al. Proapoptotic BID is required for myeloid homeostasis and tumor suppression. Genes Dev 2003;17:229-39.
42. Ryan HE, Lo J, Johnson RS. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J 1998;17:3005-15.
43. Banerjeei SK, Zoubine MN, Sarkar DK, Weston AP, Shah JH, Campbell DR. 2-Methoxyestradiol blocks estrogen-induced rat pituitary tumor growth and tumor angiogenesis: possible role of vascular endothelial growth factor. Anticancer Res 2000;20:2641-5.
44. Sweeney CJ, Miller KD, Sissons SE, et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001;61:3369-72.
45. Miller KD, Murry DJ, Curry E, et al. A phase 1 study of 2-methoxyestradiol plus docetaxel in patients with metastatic breast cancer [abstract]. Proceedings of the 38th Annual American Society of Clinical Oncology Meeting; 2002 May 18-21; Orlando, FL; American Society of Clinical Oncology, Alexandria, VA, 2002.
46. Basu A, Haldar S. Identification of a novel Bcl-xL phosphorylation site regulating the sensitivity of Taxol- or 2-methoxyestradiol-induced apoptosis. FEBS Lett 2003;538:41-7.